Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | KAT2B | Q92831 | 6/20 | 0.53 |
| ▸ | BRD9 | Q9H8M2 | 4/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | BPTF | Q12830 | 5/20 | 0.45 |
| ▸ | BRD4 | O60885 | 5/20 | 0.45 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20995545 | 0.80 | ATM (0.49) | ALDH1A1RAB9AKAT2BBRD9ATM | |
| SCHEMBL22016864 | 0.78 | ALDH1A1 (0.41) | ALDH1A1RAB9AKAT2BBRD9ATM | |
| SCHEMBL4498149 | 0.77 | RAB9A (0.55) | ALDH1A1RAB9AKAT2BBRD9ATM | |
| SCHEMBL21511152 | 0.77 | SMN1; SMN2 (0.57) | ALDH1A1RAB9AATMMAPTNPBWR1 | |
| SCHEMBL981321 | 0.76 | RAB9A (0.48) | ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL979278 | 0.75 | KAT2B (0.60) | ALDH1A1RAB9AKAT2BBRD9MAPT | |
| SCHEMBL1375635 | 0.75 | ALDH1A1 (0.50) | ALDH1A1RAB9AMAPTGAAPKM | |
| SCHEMBL14844549 | 0.74 | ALDH1A1 (0.56) | ALDH1A1RAB9AKAT2BBRD9MAPT | |
| SCHEMBL513273 | 0.74 | ALDH1A1 (0.40) | ALDH1A1RAB9AKAT2BBRD9ATM | |
| SCHEMBL22031949 | 0.74 | KAT2B (0.39) | ALDH1A1RAB9AKAT2BBRD9ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4541422-A2 | QUINOLINE DERIVATIVES AS ALPHA4BETA7 INTEGRIN INHIBITORS | Gilead Sciences, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| CN-119462635-A | Quinoline derivatives as alpha 4 beta 7 integrin inhibitors | 吉利德科学公司 | 2025-02-18 | — | — | CN | disclosed |
| US-20250032473-A1 | QUINOLINE DERIVATIVES | GILEAD SCIENCES, INC. | 2025-01-30 | — | — | US | disclosed |
| EP-3873884-B1 | 3-(QUINOLIN-8-YL)-1,4-DIHYDROPYRIDO[3,4-D]PYRIMIDIN-2,4-DIONE DERIVATIVES AS ALPHA4BETA7 INTEGRIN INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES | GILEAD SCIENCES INC (US) | 2024-12-04 | — | — | EP | disclosed |
| EP-3873605-B1 | COMPOUNDS FOR INHIBITION OF ALPHA4BETA7 INTEGRIN | GILEAD SCIENCES INC (US) | 2024-10-23 | — | — | EP | disclosed |
| CN-112969687-B | Quinoline derivatives as a4 b 7 integrin inhibitors | 吉利德科学公司 | 2024-08-23 | — | — | CN | disclosed |
| US-12053462-B2 | Quinoline derivatives | GILEAD SCIENCES, INC. (US) | 2024-08-06 | — | — | US | disclosed |
| CN-112969504-B | Compounds for inhibiting alpha 4 beta 7 integrin | 吉利德科学公司 | 2024-04-09 | — | — | CN | disclosed |
| EP-3615514-B1 | PROPIONIC ACID DERIVATIVES AND METHODS OF USE THEREOF | AVIARA PHARMACEUTICALS INC (US) | 2023-11-22 | — | — | EP | disclosed |
| US-20230265098-A1 | ALKYNE QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | ENLIVEN INC. | 2023-08-24 | — | — | US | disclosed |
| EP-1720839-A1 | PYRIDAZINONES AS ANTAGONISTS OF A4 INTEGRINS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-11-15 | — | — | EP | disclosed |
| US-20050209232-A1 | Pyridazinone ureas as antagonists of alpha4 integrins | JANSSEN PHARMACEUTICA,N.V. (BE) | 2005-09-22 | — | — | US | disclosed |
| US-20050192279-A1 | Pyridazinones as antagonists of alpha4 integrins | JANSSEN PHARAMACEUTICA, N.V. (BE) | 2005-09-01 | — | — | US | disclosed |
| WO-2005077915-A1 | PYRIDAZINONES AS ANTAGONISTS OF A4 INTEGRINS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-08-25 | — | — | WO | disclosed |
| WO-2005077915-A1 | PYRIDAZINONES AS ANTAGONISTS OF A4 INTEGRINS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-08-25 | — | — | WO | disclosed |
| WO-2005077914-A1 | PYRIDAZINONE UREAS AS ANTAGONISTS OF α4 INTEGRINS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-08-25 | — | — | WO | disclosed |
| WO-2005077914-A1 | PYRIDAZINONE UREAS AS ANTAGONISTS OF α4 INTEGRINS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-08-25 | — | — | WO | disclosed |
| EP-0352638-B1 | 5-Amino-6-pyridazinon-derivatives, process for their preparation and herbicidal agent containing them | BASF AG (DE) | 1995-02-22 | — | — | EP | disclosed |
| US-5123952-A | Postemergence herbicides | BASF AKTIENGESELLSCHAFT (DE) | 1992-06-23 | — | — | US | disclosed |
| EP-0352638-A2 | 5-Amino-6-pyridazinon-derivatives, process for their preparation and herbicidal agent containing them | BASF Aktiengesellschaft (DE) | 1990-01-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12053462-B2 | Quinoline derivatives | CFTR, NQO1, IRF3 | ALDH1A1 476/4885RAB9A 271/4885KAT2B 754/4885 |
| US-20230265098-A1 | ALKYNE QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | ERBB2, ERBB3, CHEK2 | ALDH1A1 2707/4885RAB9A 1499/4885KAT2B 4104/4885 |
| US-20050192279-A1 | Pyridazinones as antagonists of alpha4 integrins | ITGB4, ITGA4, ITGB5 | ALDH1A1 709/4885RAB9A 2416/4885KAT2B 3077/4885 |
| US-20050209232-A1 | Pyridazinone ureas as antagonists of alpha4 integrins | ITGA4, ITGB4, ITGB7 | ALDH1A1 395/4885RAB9A 2368/4885KAT2B 3121/4885 |
| US-20250032473-A1 | QUINOLINE DERIVATIVES | CFTR, NQO1, IRF3 | ALDH1A1 476/4885RAB9A 271/4885KAT2B 754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.